A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Sponsor
Eli Lilly and Company
Study ID
NCT07665879
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Eloralintide — DRUG
    Eloralintide administered SC
  • Placebo — OTHER
    Placebo administered SC

Study Details

The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in participants with obesity or overweight. For each participant, the study will last about 35 weeks and include 3 in patient visits totaling 7 days.

Key Dates

First listed
Jun 24, 2026
Start date
Jun 24, 2026
Status verified
Jul 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
115 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Eloralintide
    Eloralintide administered subcutaneously (SC)
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Change From Baseline In Hyperinsulinemic Euglycemic Clamp (HEC) Predicted Clamp-Derived Insulin Sensitivity (M-value) [ Time Frame: Baseline, Week 24 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Related Studies